(Q37705424)

22 August 2017

1 reference

title

Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials (English)

1 reference

22 August 2017

1 reference

Guru Sonpavde

1

1 reference

22 August 2017

Ganesh S Palapattu

series ordinal

2

1 reference

22 August 2017

publication date

1 March 2010

1 reference

Expert Review of Anticancer Therapy

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

439-450

1 reference

22 August 2017

cites work

Cancer statistics, 2009

1 reference

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

21 January 2018

1 reference

Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.

21 January 2018

1 reference

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

21 January 2018

1 reference

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

21 January 2018

1 reference

Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer

21 January 2018

1 reference

A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma

21 January 2018

1 reference

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

21 January 2018

1 reference

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

21 January 2018

1 reference

Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.

21 January 2018

1 reference

Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer

21 January 2018

1 reference

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 January 2018

1 reference

Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer

21 January 2018

1 reference

Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer

21 January 2018

1 reference

Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice

21 January 2018

1 reference

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer

21 January 2018

1 reference

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study

21 January 2018

1 reference

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer.

21 January 2018

1 reference

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

21 January 2018

1 reference

Preoperative versus postoperative chemoradiotherapy for rectal cancer

21 January 2018

1 reference

Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention

21 January 2018

1 reference

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer

21 January 2018

1 reference

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group

21 January 2018

1 reference

An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer

21 January 2018

1 reference

Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer

21 January 2018

1 reference

Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases

21 January 2018

1 reference

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

21 January 2018

1 reference

Phase II study of sunitinib in men with advanced prostate cancer.

21 January 2018

1 reference

Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer.

21 January 2018

1 reference

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

21 January 2018

1 reference

Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma

21 January 2018

1 reference

Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer

21 January 2018

1 reference

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.

21 January 2018

1 reference

Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients

21 January 2018

1 reference

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

21 January 2018

1 reference

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers

21 January 2018

1 reference

Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer

21 January 2018

1 reference

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology

21 January 2018

1 reference

Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer

21 January 2018

1 reference

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

21 January 2018

1 reference

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

21 January 2018

1 reference

Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms

21 January 2018

1 reference

Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.

21 January 2018

1 reference

Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811

21 January 2018

1 reference

Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer

21 January 2018

1 reference

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.10.17

1 reference

22 August 2017

1 reference